Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 19/20 | 0.57 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | CDK7 | P50613 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.42 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.42 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1944802 | 0.83 | FYN (0.63) | FYNKITPIM1FLT3CDK7 | |
| SCHEMBL1945113 | 0.81 | FYN (0.69) | FYN | |
| SCHEMBL12545036 | 0.81 | FYN (0.71) | FYN | |
| SCHEMBL2255161 | 0.80 | F2RL3 (0.42) | FYN | |
| SCHEMBL1944631 | 0.80 | FYN (0.66) | FYNKITPIM1FLT3CDK7 | |
| SCHEMBL1947243 | 0.80 | FYN (0.77) | FYN | |
| SCHEMBL1945662 | 0.80 | FYN (0.66) | FYN | |
| SCHEMBL2253064 | 0.79 | FYN (0.68) | FYNKITPIM1FLT3CDK7 | |
| SCHEMBL1946846 | 0.78 | FYN (0.60) | FYN | |
| SCHEMBL1946360 | 0.78 | MKNK1 (0.66) | FYNKITPIM1FLT3CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2193133-B1 | IMIDAZOLOTHIADIAZOLES FOR USE AS PROTEIN KINASE INHIBITORS | FUNDACIÓN CT NAC DE INVESTIGACIONES ONCOLÓGICAS CARLOS III (ES) | 2015-08-19 | — | — | EP | disclosed |
| US-8563550-B2 | Imidazolothiadiazoles for use as protein kinase inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) | 2013-10-22 | — | — | US | disclosed |
| US-20110190289-A1 | Imidazolothiadiazoles for Use as Protein Kinase Inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2011-08-04 | — | — | US | disclosed |
| CN-101878219-A | Imidazothiadiazoles for use as protein kinase inhibitors | CT NAC DE INVESTIGACIONES ONCO | 2010-11-03 | — | — | CN | disclosed |
| EP-2193133-A2 | IMIDAZOLOTHIADIAZOLES FOR USE AS PROTEIN KINASE INHIBITORS | Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) | 2010-06-09 | — | — | EP | disclosed |
| WO-2009040552-A2 | SUBSTITUTED IMIDAZO (2, 1-B) -1, 3, 4-THIAZOLE COMPOUNDS, THEIR PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190289-A1 | Imidazolothiadiazoles for Use as Protein Kinase Inhibitors | PIM1, PIM3, PIM2 | FYN 383/4885KIT 1221/4885PIM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.